Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance

Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil–based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.

(2017) Y. H. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

(2012) Kjell Magne Tveit et al.   JOURNAL OF CLINICAL ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

EGFR-targeted therapy

(2011) Loredana Vecchione et al.   EXPERIMENTAL CELL RESEARCH

Cardiovascular Toxicity of Androgen Deprivation Therapy: A New Door Opens

(2011) Shabbir M.H. Alibhai   JOURNAL OF CLINICAL ONCOLOGY

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

(2011) Monica Marra et al.   Nanomedicine-Nanotechnology Biology and Medicine

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

(2010) S. Rao et al.   ANNALS OF ONCOLOGY

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

(2010) Diane Lauren Reidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

(2010) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Downregulation of EGFR by a novel multivalent nanobody-liposome platform

(2010) Sabrina Oliveira et al.   JOURNAL OF CONTROLLED RELEASE

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy

(2009) Sarbari Acharya et al.   BIOMATERIALS

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

(2009) J Souglakos et al.   BRITISH JOURNAL OF CANCER

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

(2009) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

(2009) Laetitia Dahan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Differential tumor-targeting abilities of three single-domain antibody formats

(2009) Andrea Bell et al.   CANCER LETTERS

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Adaptive Therapy

(2009) R. A. Gatenby et al.   CANCER RESEARCH

Resistance mechanisms of tumour cells to EGFR inhibitors

(2009) Floriana Morgillo et al.   Clinical & Translational Oncology

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

(2009) H. Prenen et al.   CLINICAL CANCER RESEARCH

Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways

(2009) M. Caraglia et al.   CURRENT CANCER DRUG TARGETS

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2009) Bart Jacobs et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

(2008) D Balin-Gauthier et al.   BRITISH JOURNAL OF CANCER

Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins

(2008) M. Michaelis et al.   CLINICAL CANCER RESEARCH

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

(2008) H. Michael Shepard et al.   JOURNAL OF CLINICAL INVESTIGATION

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

(2008) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

(2008) B. M. Tijink et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE